Source comparison
Tesamorelin NASH Research: Clinical Trial Comparison
HIV+ NASH patients (Lancet HIV 2020) 2mg SC daily × 12 months 37% mean reduction in hepatic fat fraction 35% of subjects showed ≥1 stage fibrosis improvement VAT reduction preceded hepatic changes by 8–12 weeks Gold-standard trial. Longest duration, clearest m
This comparison does not assign a generated winner or score.
- HIV+ NASH patients (Lancet HIV 2020)
- 2mg SC daily × 12 months
- 37% mean reduction in hepatic fat fraction
- 35% of subjects showed ≥1 stage fibrosis improvement
- VAT reduction preceded hepatic changes by 8–12 weeks
- Gold-standard trial. Longest duration, clearest mechanistic data
- Metabolic syndrome cohort (unpublished Phase 2)
- 1mg SC daily × 6 months
- 18% mean reduction
- No fibrosis data collected
- Lower dose showed attenuated benefit
- Suggests 2mg is minimum effective dose for NASH endpoints
- Non-diabetic NAFLD (pilot study, Hepatology 2019)
- 2mg SC daily × 9 months
- 31% reduction at month 6
- Biopsy at month 9 showed 29% NAS score improvement
- IGF-1 response predicted hepatic outcome
- Confirmed mechanism is IGF-1-dependent, not GH-independent
- Obese non-NASH controls (safety trial)
- 2mg SC daily × 3 months
- 12% reduction (baseline steatosis was mild)
- N/A
- Minimal benefit in low-steatosis populations
- Tesamorelin works best in moderate-to-severe hepatic fat accumulation